AbbVie Inc.ABBV
ImmunologyNeurologyOncologyPsychiatry160 cited findings · profile updated 2026-08-26
265.79 USDnot live — refreshed daily
About AbbVie Inc.
AbbVie Inc. has an oncology research focus, with regulatory documents detailing findings for drugs like IMBRUVICA and Tepkinly. IMBRUVICA has been studied in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), with safety findings including Grade 3 or higher bleeding events in 6% of patients and Grade 3 or 4 thrombocytopenia ranging from 5 to 17%. Tepkinly, another oncology agent, showed Grade ≥3 TEAEs in 68.7% across all B-NHL pool 01+04 and 65.9% in LBCL pool 01. Fatal (Grade 5) TEAEs were reported at 7.2% for Tepkinly.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Infections Grade 3 or greater (CLL) | 26 % | PHARMACYCLICS LLC — Imbruvica FDA Review (NDA/BLA 205552, 2017), p.13 |
| Infections Grade 3 or greater (MCL) | 25 % | PHARMACYCLICS LLC — Imbruvica FDA Review (NDA/BLA 205552, 2017), p.13 |
| Grade 3 or higher bleeding events | 6 % | PHARMACYCLICS LLC — Imbruvica FDA Review (NDA/BLA 205552, 2017), p.12 |
| Grade ≥3 TEAEs (All B-NHL pool 01+04) | 68.7 % | AbbVie Inc. — Tepkinly EMA EPAR public assessment report (EMEA/H/C/005, p.204 |
| Fatal (Grade 5) TEAEs | 7.2 % | AbbVie Inc. — Tepkinly EMA EPAR public assessment report (EMEA/H/C/005, p.203 |
| Grade 3 or 4 thrombocytopenia | 5 to 17 % | PHARMACYCLICS LLC — Imbruvica FDA Review (NDA/BLA 205552, 2017), p.13 |
Key projects
- IMBRUVICA (Chronic Lymphocytic Leukemia)
Infections Grade 3 or greater were observed in 26% of subjects with IMBRUVICA in CLL.
- IMBRUVICA (Mantle Cell Lymphoma)
Infections Grade 3 or greater were observed in 25% of subjects with IMBRUVICA in MCL.
- Tepkinly (B-NHL)
Grade ≥3 TEAEs were reported in 68.7% of subjects in the All B-NHL pool 01+04 for Tepkinly.
- Tepkinly (MCL)
Grade 3 or 4 CRS in GCT3013-01 MCL expansion cohort was 10.8% for Tepkinly.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →